FI121073B - Metod för att skydda celler - Google Patents

Metod för att skydda celler Download PDF

Info

Publication number
FI121073B
FI121073B FI20085973A FI20085973A FI121073B FI 121073 B FI121073 B FI 121073B FI 20085973 A FI20085973 A FI 20085973A FI 20085973 A FI20085973 A FI 20085973A FI 121073 B FI121073 B FI 121073B
Authority
FI
Finland
Prior art keywords
cells
complement
factor
stem cells
cell
Prior art date
Application number
FI20085973A
Other languages
English (en)
Finnish (fi)
Other versions
FI20085973A0 (sv
FI20085973A (sv
Inventor
Jukka Partanen
Taina Jaatinen
Seppo Meri
Sami Junnikkala
Jarmo Laine
Original Assignee
Suomen Punainen Risti Veripalv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suomen Punainen Risti Veripalv filed Critical Suomen Punainen Risti Veripalv
Priority to FI20085973A priority Critical patent/FI121073B/sv
Publication of FI20085973A0 publication Critical patent/FI20085973A0/sv
Priority to EP09759743A priority patent/EP2358354A2/en
Priority to CA2740762A priority patent/CA2740762A1/en
Priority to US13/123,818 priority patent/US20110217724A1/en
Priority to PCT/FI2009/050833 priority patent/WO2010043772A2/en
Priority to AU2009305331A priority patent/AU2009305331B2/en
Publication of FI20085973A publication Critical patent/FI20085973A/sv
Application granted granted Critical
Publication of FI121073B publication Critical patent/FI121073B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/505—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (6)

1. Förfarande för att skydda mesenkymala eller hematopoietiska stamceller eller en frän navelsträngsblod erhällen cell mot förstörelse som ett 5 komplementsystem ästadkommer genom att använda ätminstone en komple-mentinhiberande faktor, som har valts frän följande: faktor H, CR1, MCP och DAF.
2. Förfarande enligt patentkrav 1,kännetecknat av att stam-cellerna är i ett kliniskt transplantat, tili vilket ätminstone en komplementinhibe- 10 rande faktor tillsätts.
3. Förfarande enligt patentkrav 1 eller 2, k ä n n e t e c k n a t av att komplementsystemet aktiveras med en pä cellens yta befintlig icke-human Neu5Gc-struktur.
4. Användning av en komplementinhiberande faktor, som har valts 15 frän följande: faktor H, CR1, MCP och DAF, för att skydda mesenkymala och/eller hematopoietiska stamceller i ett kliniskt transplantat mot förstörelse som ästadkommits av ett komplementsystem.
5. Användning enligt patentkrav 4, k ä n n e t e c k n a t av att komplementsystemet aktiveras med en pä cellens yta befintlig icke-human
20 Neu5Gc-struktur.
6. Komposition eller blandning, som omfattar mesenkymala och/eller hematopoietiska stamceller och ätminstone en komplementinhiberande faktor, som har valts frän följande: faktor H, CR1, MCP och DAF.
FI20085973A 2008-10-15 2008-10-15 Metod för att skydda celler FI121073B (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20085973A FI121073B (sv) 2008-10-15 2008-10-15 Metod för att skydda celler
EP09759743A EP2358354A2 (en) 2008-10-15 2009-10-15 Method of protecting cells
CA2740762A CA2740762A1 (en) 2008-10-15 2009-10-15 Method of protecting cells
US13/123,818 US20110217724A1 (en) 2008-10-15 2009-10-15 Method of protecting cells
PCT/FI2009/050833 WO2010043772A2 (en) 2008-10-15 2009-10-15 Method of protecting cells
AU2009305331A AU2009305331B2 (en) 2008-10-15 2009-10-15 Method of protecting cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20085973A FI121073B (sv) 2008-10-15 2008-10-15 Metod för att skydda celler
FI20085973 2008-10-15

Publications (3)

Publication Number Publication Date
FI20085973A0 FI20085973A0 (sv) 2008-10-15
FI20085973A FI20085973A (sv) 2010-04-16
FI121073B true FI121073B (sv) 2010-06-30

Family

ID=39924616

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20085973A FI121073B (sv) 2008-10-15 2008-10-15 Metod för att skydda celler

Country Status (5)

Country Link
US (1) US20110217724A1 (sv)
EP (1) EP2358354A2 (sv)
CA (1) CA2740762A1 (sv)
FI (1) FI121073B (sv)
WO (1) WO2010043772A2 (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014206414A1 (en) * 2013-06-28 2014-12-31 Region Syddanmark Complement factor h for use in the treatment of bone diseases
US20200325449A1 (en) * 2016-06-02 2020-10-15 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
CA2522104A1 (en) * 2003-04-16 2004-10-28 Novartis Ag Vav inhibition in graft rejection
WO2007016099A2 (en) * 2005-07-29 2007-02-08 Musc Foundation For Research Development Protection of transplanted stem cells with hmg-coa reductase inhibitors

Also Published As

Publication number Publication date
EP2358354A2 (en) 2011-08-24
FI20085973A0 (sv) 2008-10-15
FI20085973A (sv) 2010-04-16
WO2010043772A8 (en) 2010-06-10
AU2009305331A1 (en) 2010-04-22
CA2740762A1 (en) 2010-04-22
WO2010043772A2 (en) 2010-04-22
US20110217724A1 (en) 2011-09-08
WO2010043772A3 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
Hellström et al. Colony inhibition of fibroblasts from chimeric dogs mediated by the dogs' own lymphocytes and specifically abrogated by their serum
Böhmig et al. Strategies to overcome the ABO barrier in kidney transplantation
Lemoli et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells
Bacigalupo et al. Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma lymphocytes.
Dennert et al. Phagocytic cells as effectors in a cell-mediated immunity system
Körbling et al. 4‐Hydroperoxyclophosphamide: a model for eliminating residual human tumour cells and T‐lymphocytes from the bone marrow graft
Ide et al. Antibody‐and complement‐independent phagocytotic and cytolytic activities of human macrophages toward porcine cells
JPWO2009020201A1 (ja) 単離された細胞集団
FI121073B (sv) Metod för att skydda celler
Mitsuzawa et al. Induced pluripotent stem cell‐derived mesenchymal stem cells prolong hind limb survival in a rat vascularized composite allotransplantation model
Guo et al. Efficacy and mechanisms underlying the effects of allogeneic umbilical cord mesenchymal stem cell transplantation on acute radiation injury in tree shrews
Rafiee et al. A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes
JP2000001436A (ja) Ｎｋ細胞媒介性免疫応答の誘導方法
Li et al. Abnormalities of myeloid progenitor cells after
DK2717887T3 (en) Methods for treating or preventing graft-versus-host disease
Li et al. Blocking L‐selectin and α4‐integrin changes donor cell homing pattern and ameliorates murine acute graft versus host disease
Yang et al. CD150highTreg cells may attenuate graft versus host disease and intestinal cell apoptosis after hematopoietic stem cell transplantation
WO2002055095A2 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
He et al. Heme oxygenase‐1 attenuates the inhibitory effect of bortezomib against the APRIL‐NF‐κB‐CCL3 signaling pathways in multiple myeloma cells: Corelated with bortezomib tolerance in multiple myeloma
Yunis et al. Involution of the thymus dependent lymphoid system
Roy et al. Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model
Xu et al. Marrow graft rejection by repeated transfusions of allogeneic donor spleen cells
AU2009305331B2 (en) Method of protecting cells
EP3811952A1 (en) Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
Preti et al. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 121073

Country of ref document: FI

MM Patent lapsed